A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan

PHASE4RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

November 30, 2025

Conditions
Primary Hypercholesterolemia or Mixed Hyperlipidemia
Interventions
DRUG

Bempedoic acid 180 mg tablet

180 mg tablet, once daily administered for 12 weeks

Trial Locations (3)

220

RECRUITING

Far Eastern Memorial Hospital, New Taipei City

333

RECRUITING

Linkou Chang Gung Memorial Hospital, Taoyuan District

807

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT06925100 - A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan | Biotech Hunter | Biotech Hunter